UPDATE: Intellia Therapeutics (NTLA) PT Lowered to $83 at Morgan Stanley (correction)

Morgan Stanley analyst Terence Flynn lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $83.00 (from $84.00) while maintaining a Overweight rating.

The analyst comments "NTLA reported 3Q22 results, but focus remains on pipeline progress, where NTLA will present new '2002 HAE data Nov 12 and likely incremental '2001 ATTR-CM data Nov 5. We see the upside valuation case for NTLA as compelling."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities